Covid-19 roundup: Tiny sample size leads FDA to turn down Rigel's EUA; Seattle biotech to co-develop mRNA vaccine in South Korea

Four months after Rigel announced possible Phase II results for its Covid-19 treatment, the FDA has deemed the sample size too …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Tiny sam­ple size leads FDA to turn down Rigel's EUA; Seat­tle biotech to co-de­vel­op mR­NA vac­cine in South Ko­rea